COVALAB S.A.R.L

In the biotechnology industry where the creation of any start-up depends on the input of the investors and on the fluctuations of the stock market, Covalab stands out as an exception. Indeed, with a minimum of initial capital and the assistance of University Claude Bernard (Lyon), the company developed slowly using as its foundation its know-how in Immunochemistry.

The principal aim of its founding members (Dr. Saïd El Alaoui & Dr. Vincent Thomas) was to achieve national and international credibility. This is an original concept, a slow but worthwhile process, on the condition that it evolves according to the needs of the industry and remains firmly rooted in practical achievements. Covalab principal activity, which has allowed it to attain complete financial independence, is that devoted to the development of monoclonal & polyclonal antibodies destined for research, diagnosis and therapeutics.

Some of the antibodies developed for pharmaceutical companies are among products having a strong potential for clinical application. Covalab also has its own wide range of products for research and diagnosis in areas as varied as cancer, neuroscience, auto-immune diseases, to mention only a few.